T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

F. Schettini, B. Conte, G. Buono, P. De Placido, S. Parola, G. Griguolo, A. Fabi, C. Bighin, F. Riccardi, D. Cianniello, M. De Laurentiis, F. Puglisi, G. Pelizzari, M. Bonotto, S. Russo, A. Frassoldati, A. Pazzola, F. Montemurro, M. Lambertini, V. Guarneri, F. Cognetti, M. Locci, D. Generali, P. Conte, S. De Placido, M. Giuliano, G. Arpino, L. Del Mastro

Open source

DOI: 10.1016/j.esmoop.2021.100099
Published: 2021-04
Container: ESMO Open
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2021.100099,
  title = {T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study},
  author = {F. Schettini and B. Conte and G. Buono and P. De Placido and S. Parola and G. Griguolo and A. Fabi and C. Bighin and F. Riccardi and D. Cianniello and M. De Laurentiis and F. Puglisi and G. Pelizzari and M. Bonotto and S. Russo and A. Frassoldati and A. Pazzola and F. Montemurro and M. Lambertini and V. Guarneri and F. Cognetti and M. Locci and D. Generali and P. Conte and S. De Placido and M. Giuliano and G. Arpino and L. Del Mastro},
  year = {2021},
  journal = {ESMO Open},
  doi = {10.1016/j.esmoop.2021.100099},
  url = {https://doi.org/10.1016/j.esmoop.2021.100099}
}

RIS

TY  - JOUR
TI  - T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
AU  - F. Schettini
AU  - B. Conte
AU  - G. Buono
AU  - P. De Placido
AU  - S. Parola
AU  - G. Griguolo
AU  - A. Fabi
AU  - C. Bighin
AU  - F. Riccardi
AU  - D. Cianniello
AU  - M. De Laurentiis
AU  - F. Puglisi
AU  - G. Pelizzari
AU  - M. Bonotto
AU  - S. Russo
AU  - A. Frassoldati
AU  - A. Pazzola
AU  - F. Montemurro
AU  - M. Lambertini
AU  - V. Guarneri
AU  - F. Cognetti
AU  - M. Locci
AU  - D. Generali
AU  - P. Conte
AU  - S. De Placido
AU  - M. Giuliano
AU  - G. Arpino
AU  - L. Del Mastro
PY  - 2021
JO  - ESMO Open
DO  - 10.1016/j.esmoop.2021.100099
UR  - https://doi.org/10.1016/j.esmoop.2021.100099
ER  -

APA

Schettini, F., Conte, B., Buono, G., Placido, P. D., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., Laurentiis, M. D., Puglisi, F., Pelizzari, G., Bonotto, M., Russo, S., Frassoldati, A., Pazzola, A., Montemurro, F., Lambertini, M., Guarneri, V., Cognetti, F., Locci, M., Generali, D., Conte, P., Placido, S. D., Giuliano, M., Arpino, G., & Mastro, L. D. (2021). T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO Open. https://doi.org/10.1016/j.esmoop.2021.100099

Source records

crossref · retrieved 2026-09-27T14:34:09.601Z